Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows

v3.25.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
OPERATING ACTIVITIES    
Net loss $ (267) $ (1,112)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Provision for doubtful accounts 45 (130)
Depreciation 3,072 2,652
Loss (gain) on disposal of and reserve adjustments for medical equipment 257 (43)
Gain on sale of medical equipment (838) (629)
Amortization of intangible assets 248 248
Amortization of deferred debt issuance costs 19 19
Stock-based compensation 1,108 1,057
Deferred income taxes 520 (186)
Changes in assets - (increase)/decrease:    
Accounts receivable (2,095) (237)
Inventories 433 153
Other current assets 126 (685)
Other assets 729 376
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (1,577) (1,106)
NET CASH PROVIDED BY OPERATING ACTIVITIES 1,780 377
INVESTING ACTIVITIES    
Purchase of medical equipment (3,284) (1,493)
Purchase of property and equipment (131) (182)
Proceeds from sale of medical equipment, property and equipment 754 1,257
NET CASH USED IN INVESTING ACTIVITIES (2,661) (418)
FINANCING ACTIVITIES    
Principal payments on long-term debt (14,407) (15,258)
Cash proceeds from long-term debt 19,231 16,069
Common stock repurchased as part of share repurchase program (2,895) 0
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (228) (365)
Cash proceeds from exercise of options and ESPP 159 186
NET CASH PROVIDED BY FINANCING ACTIVITIES 1,860 632
Net change in cash and cash equivalents 979 591
Cash and cash equivalents, beginning of period 527 231
Cash and cash equivalents, end of period $ 1,506 $ 822